$NVO 0.52 Developing

Notable posts

• @StockSavvyShay bullish 816 eng

  10 STOCKS TRADING NEAR DECADE-LOW VALUATION MULTIPLES 1. $MSFT | Microsoft 2. $NFLX | Netflix 3. $MA | Mastercard 4. $MELI | MercadoLibre 5. $SE | Sea Limited 6. $PYPL | PayPal 7. $NVO | Novo Nordisk 8. $CRM | Salesforce 9. $ADBE | Adobe 10. $LULU | Lululemon

  view on X →
• @Mr_Derivatives bullish 290 eng

  $NVO Watchlist for a big breakout here from a multi yr down trendline break? https://t.co/RzH7HoVRut

  view on X →
• @wallstengine neutral 223 eng

  NOVO NORDISK PLANS CHINA FILING FOR ORAL WEGOVY $NVO's CEO told Reuters the company plans to seek Chinese regulatory approval for its Wegovy weight-loss pill “very soon,” likely within a few months. The move comes as Novo races Eli Lilly in China’s obesity market, where Lilly has already submitted its oral GLP-1 application. Novo also faces pressure from semaglutide patent expiry in China and expected generic competition starting next year.

  view on X →
• @wallstengine bearish 202 eng

  NOVO NORDISK ZILTIVEKIMAB FAILS PHASE 3 ZEUS TRIAL The once-monthly IL-6 inhibitor was tested in more than 6,300 patients with cardiovascular disease, chronic kidney disease and elevated inflammation. $NVO's Ziltivekimab did not reduce cardiovascular death, nonfatal heart attack or nonfatal stroke versus placebo. The hazard ratio was 0.99, with a 95% confidence interval of 0.88 to 1.11. The drug lowered IL-6 and hsCRP as expected, but those biological effects did not translate into fewer cardiovascular events. Overall adverse-event rates were similar, although serious infections were more common with ziltivekimab. All-cause mortality was unchanged. Novo said the result will not affect its 2026 adjusted operating-profit outlook but will trigger a Q3 noncash impairment. The HERMES and ARTEMIS trials will continue, with results expected in H1 2027. Source: Novo Nordisk

  view on X →
• @StockSavvyShay bearish 192 eng

  $NVO experimental drug "ziltivekimab" failed to reduce cardiovascular death, heart attack or stroke despite lowering key inflammation markers. Novo says 2026 guidance is unchanged but will record a Q3 noncash impairment while two additional trials continue. https://t.co/jFE33etW7D

  view on X →
• @wallstengine neutral 132 eng

  Novo Nordisk $NVO sues Eli Lilly $LLY over allegedly misleading GLP-1 ads Novo claims Lilly compares the highest doses of Zepbound and Mounjaro against lower doses of Wegovy and Ozempic, while omitting newer approved dosing options. Novo is seeking a permanent injunction and corrective advertising, and may ask the court to block the campaigns immediately if Lilly does not pull them voluntarily.

  view on X →
• @wallstengine neutral 94 eng

  $NVO CEO Mike Doustdar is looking beyond obesity and diabetes, pointing to potential GLP-1 expansion into longevity and aesthetics, per Bloomberg. Doustdar highlighted research showing semaglutide may protect organs like the heart, liver, and kidneys, with some benefits appearing before major weight loss. Novo is also asking scientists to study what future GLP-1 drugs could target beyond weight loss, including areas like inflammation, knee pain, skincare, and hair loss.

  view on X →
• @wallstengine neutral 88 eng

  Novo Nordisk $NVO says Wegovy is now available to eligible Medicare beneficiaries living with obesity through its Medicare GLP-1 Bridge program. Eligible patients can access Wegovy for a $50 monthly copay, with the program running through the end of 2027. https://t.co/SUjiIpa15i

  view on X →